-SEC 8K Filing
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/30/2023 | Buy → Neutral | ROTH MKM | |
| 3/21/2023 | $11.00 | Outperform | SVB Securities |
| 1/31/2023 | $21.00 | Buy | ROTH Capital |
| 1/23/2023 | $18.00 | Buy | Mizuho |
| 9/12/2022 | $10.00 | Buy | H.C. Wainwright |
| 4/1/2022 | $15.00 | Outperform | Oppenheimer |
| 9/14/2021 | $22.00 | Neutral | Goldman |
| 7/20/2021 | $25.00 | Overweight | Piper Sandler |
4 - Rain Oncology Inc. (0001724979) (Issuer)
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights Pathos AI, Inc. ("Pathos") today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. ("Merger Sub"), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc. (NASDAQ:RAIN) ("Rain") for $1.16 per share in cash plus one contingent value right per share (each, a "CVR"), which CVR shall represent the right to receive potential payments pursuant to the terms and subject to the conditions of the Contingent Value Rights Agreement, dated as of January 26, 2024, by and among Pathos, Merger Sub, Equiniti Trust Company, LLC, and Forti
NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN) ("Rain"), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. ("Pathos") will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a "CVR") for potential cash payments of up to approximately $0.17 per share. The Rain Board of Directors voted unanimously to approve the proposed Offer, Merger and related transactions contemplated by the Merger Agreement (collectively, the "Transaction"). The upfront cash consideration represents a 17% premium over Rain's unaffected stock price as of October 13, 2023. The Rain Board reached this determinati
NEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on the Company's key developments and business operations. "Rain continues to evaluate a number of strategic opportunities to add value for its stockholders," said Avanish Vellanki, co-founder and chief executive officer of Rain. "We anticipate being able to provide a public update on our efforts before the end of the year." Third Quarter 2023 Financial Highlights For the three and nine months ended September 30, 2023, Rain reported a net loss of $7.0 million and $49.6 million, respect
SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)
ROTH MKM downgraded Rain Oncology from Buy to Neutral
SVB Securities initiated coverage of Rain Oncology with a rating of Outperform and set a new price target of $11.00
ROTH Capital resumed coverage of Rain Oncology with a rating of Buy and set a new price target of $21.00
15-12G - Rain Oncology Inc. (0001724979) (Filer)
EFFECT - Rain Oncology Inc. (0001724979) (Filer)
S-8 POS - Rain Oncology Inc. (0001724979) (Filer)
4 - Rain Oncology Inc. (0001724979) (Issuer)
4 - Rain Oncology Inc. (0001724979) (Issuer)
4 - Rain Oncology Inc. (0001724979) (Issuer)
-SEC 8K Filing
Rain Oncology Inc (NASDAQ:RAIN) has agreed to be acquired by Pathos AI Inc. for $1.16 in cash per share plus a non-tradeable contingent value right (CVR) for potential cash payments of up to approximately $0.17 per share. The upfront cash consideration represents a 17% premium over Rain's unaffected stock price as of October 13, 2023. "After a thorough assessment, the Rain Board determined that this Transaction is in the best interests of our stockholders, as it leverages Rain's strong cash position to provide a confirmed cash takeout for our stockholders and retains some future potential upside due to Pathos' continued interest in further developing milademetan for cancer patients using
Pursuant and subject to the terms of the merger agreement, a subsidiary of Pathos will commence a tender offer to acquire all outstanding shares of Rain for $1.16 in cash per share plus a CVR representing a contractual right to receive two potential contingent aggregate cash payments as follows: Cash CVR Payment: an aggregate amount equal to $5.0 million (up to approximately $0.14 per share), minus (A) certain expenses incurred related to pending or future litigation involving Rain and its directors or officers, minus (B) any shortfall in a target level of net cash, plus (C) any cash at closing in excess of the target net cash. Development CVR Payment: either (i) $1.0 million (approximat
– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. "Rain has been aggressively pursuing a multitude of opportunities as we seek to leve
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain") today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: August 10, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers: 1 (888) 886-7786 (U.S. Toll Free) / 1 (416) 764-8658 (International)Conference ID: 29873479Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1624922&tp_key=7933f8175f A replay of the ca
– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with a hazard ratio of 0.89 – – Rain to host a conference call at 8:30 a.m. ET – NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and tolerability of milademetan in p